Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA to Set Numerical Goals for OTC Drugs, Generics
January 5, 2009
- Yakult Licenses ThermoDox from Celsion
January 5, 2009
- REGULATORY NEWS IN BRIEF
January 5, 2009
- Diovan Ranked No. 1 on Both GP and HP Markets: Rep Track Survey
January 5, 2009
- GSK to Directly Compare Pazopanib with Sunitinib in RCC
January 5, 2009
- Combinations of Physical Detailing and e-Detailing Have Varying Effects, Depending on Drug Category
January 5, 2009
- Eldecalcitol Reduces Incidence of New Vertebral Fractures: Chugai, Taisho
January 5, 2009
- JMHA Considers Joint Purchases
January 5, 2009
- JSCPT Symposium Focuses on Adaptive Design
January 5, 2009
- % of Patients on Drugs for Hypertension Lowest in Japan: 15-Country Survey
January 5, 2009
- Japan Needs Basic Systems for Global Clinical Trials: Prof. Ohashi
January 5, 2009
- Promotion of Use of Generics Essential to Have Industry-Proposed Pricing System Introduced
January 5, 2009
- Conduct Clinical Development Based on Assumption That There Are Ethnic Differences
January 5, 2009
- Korosho Asks Insurers to Participate in Councils for Promotion of the Use of Generics
January 5, 2009
- R&D NEWS IN BRIEF
January 5, 2009
- Korosho to Provide ¥20 Bil. by Promoting Use of Generics
January 5, 2009
- JPhA to Demand Direct Talk with Korosho
January 5, 2009
- JHIA to Promote Use of Generics
January 5, 2009
- Etizolam, Loxoprofen Taken during Pregnancy Don't Increase Incidence of Malformations
January 5, 2009
- Global Sales of Generics Totaled US$78.0 Bil. in 2007
January 5, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…